Top

Published in:

01-10-2020 | Parkinson's Disease | Original Communication

Association between dopaminergic medications and REM sleep behavior disorder in Parkinson’s disease: a preliminary cohort study

Authors: Mario Meloni, Marco Bortolato, Antonino Cannas, Ilaria Laccu, Michela Figorilli, Patrizia Congiu, Giovanni Defazio, Federico Meloni, Monica Puligheddu

Published in: Journal of Neurology | Issue 10/2020

Abstract

Background

Rapid eye movement sleep behavior disorder (RBD) is highly comorbid with Parkinson’s disease (PD). Emerging evidence suggests that dopamine-replacement therapies (DRTs) for PD may modify the course of RBD, yet the nature of the association between DRTs and RBD remains unclear. To begin addressing this issue, we conducted a preliminary retrospective study to document whether DRTs are associated with the occurrence of RBD symptoms in PD patients.

Methods

The study included 250 PD patients who were screened for probable RBD via the RBD Screening Questionnaire (RBDSQ). For each patient, disease severity data were collected, in addition to their therapy and the associated levodopa equivalent daily dose (LEDD). The association between DRTs and RBDSQ scores was analyzed using logistic regression and correlation models.

Results

RBD scores were found to be associated with the LEDD of levodopa alone, but not of dopaminergic agonists (mainly D2/D3 receptor agonists) or their combination with levodopa. This association was not accounted for patient age or Hoehn and Yahr (H&Y) severity scores.

Conclusions

Our study detected a significant association between doses of levodopa and RBD symptoms in PD patients. Future longitudinal studies are needed to establish what causal nexus may link these variables.

Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW (1986) Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. https://doi.org/10.1093/sleep/9.2.293CrossRefPubMed

American Academy of Sleep Medicine (2005) International Classification of Sleep Disorders: Diagnostic and Coding Manual. (ICSD-2)

Comella CL, Nardine TM, Diederich NJ, Stebbins GT (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology. https://doi.org/10.1212/WNL.51.2.526CrossRefPubMed

Boeve BF, Silber MH, Ferman TJ et al (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16(4):622–630. https://doi.org/10.1002/mds.1120CrossRefPubMed

Boeve BF (2010) REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 1184:15–54. https://doi.org/10.1111/j.1749-6632.2009.05115.xCrossRefPubMedPubMedCentral

Takakusaki K, Saitoh K, Harada H et al (2004) Evidence for a role of basal ganglia in the regulation of rapid eye movement sleep by electrical and chemical stimulation for the pedunculopontine tegmental nucleus and the substantia nigra pars reticulata in decerebrate cats. Neuroscience. https://doi.org/10.1016/j.neuroscience.2003.10.028CrossRefPubMed

Verhave PS, Jongsma MJ, Smit AB et al (2011) REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep. https://doi.org/10.5665/sleep.1174CrossRefPubMedPubMedCentral

Lima MMS (2013) Sleep disturbances in Parkinson’s disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev 17(5):367–375. https://doi.org/10.1016/j.smrv.2012.10.006CrossRefPubMed

Kim YE, Jeon BS, Yang HJ et al (2014) REM sleep behavior disorder: association with motor complications and impulse control disorders in Parkinson’s disease. Park Relat Disord. https://doi.org/10.1016/j.parkreldis.2014.03.022CrossRef

10.

Schmidt MH, Koshal VB, Schmidt HS (2006) Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. https://doi.org/10.1016/j.sleep.2006.03.018CrossRefPubMed

11.

Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (2012) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. https://doi.org/10.1212/wnl.42.6.1142CrossRefPubMed

12.

Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. https://doi.org/10.1002/mds.23429CrossRefPubMed

13.

Stiasny-Kolster K, Mayer G, Schäfer S et al (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord. https://doi.org/10.1002/mds.21740CrossRefPubMed

14.

Nomura T, Inoue Y, Kagimura T et al (2011) Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients. Sleep Med. https://doi.org/10.1016/j.sleep.2011.01.015CrossRefPubMed

15.

Yong MH, Fook-Chong S, Pavanni R et al (2011) Case control polysomnographic studies of sleep disorders in Parkinson’s disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0022511CrossRefPubMedPubMedCentral

16.

Kim HJ, Park SY, Cho YJ et al (2009) Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci. https://doi.org/10.1016/j.jns.2009.07.026CrossRefPubMed

17.

Eisensehr I, Linke R, Noachtar S et al (2000) Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain. https://doi.org/10.1093/brain/123.6.1155CrossRefPubMed

18.

Trampus M, Ferri N, Adami M, Ongini E (1993) The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur J Pharmacol. https://doi.org/10.1016/0014-2999(93)90823-ZCrossRefPubMed

19.

Zoetmulder M, Nikolic M, Biernat H et al (2016) Increased motor activity during REM sleep is linked with dopamine function in idiopathic REM sleep behavior disorder and Parkinson disease. J Clin Sleep Med. https://doi.org/10.5664/jcsm.5896CrossRefPubMedPubMedCentral

20.

Garcia-Borreguero D, Caminero AB, de la Llave Y et al (2002) Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson’s diseae: effects of treatment with levodopa and progression of illness. Mov Disord 17(5):934–941. https://doi.org/10.1002/mds.10233CrossRefPubMed

21.

Halsband C, Zapf A, Sixel-Döring F et al (2018) The REM sleep behavior disorder screening questionnaire is not valid in de novo Parkinson’s disease. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.12591CrossRefPubMedPubMedCentral

22.

Miyamoto T, Miyamoto M, Iwanami M et al (2009) The REM sleep behavior disorder screening questionnaire: validation study of a Japanese version. Sleep Med. https://doi.org/10.1016/j.sleep.2009.05.007CrossRefPubMed

Title: Association between dopaminergic medications and REM sleep behavior disorder in Parkinson’s disease: a preliminary cohort study
Authors: Mario Meloni
Marco Bortolato
Antonino Cannas
Ilaria Laccu
Michela Figorilli
Patrizia Congiu
Giovanni Defazio
Federico Meloni
Monica Puligheddu
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Parkinson's Disease
Levodopa
Dopamine Agonist
Published in: Journal of Neurology / Issue 10/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09956-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between dopaminergic medications and REM sleep behavior disorder in Parkinson’s disease: a preliminary cohort study

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2020

Dyspnea after subthalamic deep brain stimulation in Parkinson’s disease: a case–control study

Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis

COVID-19-associated acute disseminated encephalomyelitis (ADEM)

COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF

A novel conversion prediction method of MCI to AD based on longitudinal dynamic morphological features using ADNI structural MRIs

Early functional MRI changes in a prodromal semantic variant of primary progressive aphasia: a longitudinal case report